{"id":"W3169728670","doi":"10.1200/jco.2021.39.15_suppl.4518","title":"PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Cisplatin; Cystectomy; Cohort; Bladder cancer; Urology; Internal medicine; Oncology; Neoadjuvant therapy; Clinical endpoint; Nivolumab; Chemotherapy; Gastroenterology; Cancer; Randomized controlled trial; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001617906,0.001412904,0.001366174,0.0003003935,0.0004572447,0.001248424,0.001376086,0.00156195,0.008234781],"category_scores_gemma":[0.001008133,0.0006974503,0.001215266,0.0002908746,0.001159112,0.001271144,0.0006442469,0.004148185,0.002179852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00116706,"about_ca_system_score_gemma":0.002755474,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007364773,"about_ca_topic_score_gemma":0.003533129,"domain_scores_codex":[0.999537,0.0002334887,0.00001919837,0.00007989967,0.00003759049,0.00009297978],"domain_scores_gemma":[0.9991797,0.0001074249,0.0001582371,0.00006329174,0.0000528155,0.000438664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7720073,0.07799432,0.005893884,0.001360046,0.0009579143,0.0001721815,0.0002927417,0.001721546,0.0287388,0.0004943195,0.009788703,0.1005783],"study_design_scores_gemma":[0.4688506,0.5161251,0.006575083,0.00007564461,0.000313829,0.0002476115,0.0000926575,0.000732183,0.001923179,0.0002750902,0.004754461,0.000034535],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9812734,0.002322394,0.0005707399,0.00118419,0.0002830708,0.006320827,0.002458303,0.0002549349,0.005332102],"genre_scores_gemma":[0.9686705,0.001960247,0.003852511,0.002557821,0.0002778641,0.01082036,0.005312438,0.00006885179,0.006479443],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008234781,"threshold_uncertainty_score":0.02754807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1362449787260494,"score_gpt":0.4857202627915511,"score_spread":0.3494752840655017,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}